Based on the summarized literature, we conclude that there might be a role for intestinal reelin in the pathogenesis of depression and that reelin-based therapeutics could serve as a putative novel avenue better targeting the nature of depression at a multidimensional level. This evidence concerns the gene RELN and depressive symptom measurement.